Aidoc Raises $150 Million to Expand Clinical AI into Oncology and Cardiovascular Disease

Aidoc, a healthcare artificial intelligence company, has secured $150 million in new financing to advance its clinical AI capabilities. The company plans to expand its solutions into oncology and cardiovascular disease, aiming to assist clinicians with decision-making and diagnosis. This bold move highlights Aidoc’s growing commitment to oncology innovation and addressing some of the most pressing challenges in cancer care.

The company’s technology includes foundation-model-powered clinical AI solutions. In February, Aidoc received clearance from the U.S. Food and Drug Administration for its CADt AI solution, which is used for triaging rib fractures. Two of its solutions powered by the Clinical AI Reasoning Engine (CARE) foundation model have now received FDA clearance. The company recently announced two enterprise-wide rollouts at Advocate Health and Sutter Health, with plans to expand into oncology solutions that directly enhance cancer diagnostics.

The $150 million round was led by General Catalyst and Square Peg, with additional participation from NVentures, Nvidia’s venture capital arm. Sutter Health, Hartford, Mercy, and WellSpan also joined the round as strategic investors. A $40 million revolving credit facility was included in this financing, bringing Aidoc’s total funding to $370 million—capital that will help accelerate oncology–driven AI development alongside cardiovascular and other specialties.

Aidoc, founded in 2016, offers tools in radiology, cardiology, neurovascular, and vascular fields. The company intends to expand into oncology to address critical cancer diagnostics. Aidoc currently supports the care of more than 45 million patients annually across over 150 health systems and aims to reach 100 million patients within three years. Its partners include Mount Sinai Health System, Yale New Haven Health System, University of Miami, Temple Health, and Northwell Health—all of which could benefit from scalable oncology applications in the near future.

“Our mission is to reduce diagnostic errors and improve patient outcomes,” said Elad Walach, CEO of Aidoc. He added that CARE “compresses decades of roadmap into years—bringing forward a future where AI supports every patient encounter, including advanced oncology insights, helping physicians provide the care they believe their patients deserve.”

The company’s aiOS platform is an enterprise operating system that allows health systems to deploy and manage multiple solutions, including real-time performance tracking, integration, and outcome measurement. The platform supports both Aidoc and third-party models, and will serve as the backbone for new oncology diagnostic solutions.

Aidoc has a collaboration with Amazon Web Services to strengthen aiOS and works with Nvidia to develop BRIDGE, a set of guidelines for AI implementation. The company says it will invest over $150 million to bring the CARE foundation model to market through its partnerships with AWS and Nvidia. These efforts are focused on combining high-performance computing and development platforms to improve model performance, efficiency, and real-time inference—critical factors for accelerating oncology advancements.

According to company executives, Aidoc’s clinical tools are designed to flag high-risk findings, automate follow-ups, and expedite patient care. Roxanna Gapstur, Ph.D., president and CEO of WellSpan Health, stated, “In one year, Aidoc has helped our radiologists to analyze more than 200,000 cases, making efficient the work of scanning what can sometimes be thousands of images per case, leading to a significant reduction of critical diagnosis delays.” She emphasized that such capabilities are especially valuable for oncology workloads, where early detection is often lifesaving.

Aidoc claims its CARE foundation model powers FDA-cleared applications and accelerates the development of new indications up to 20 times faster. The company plans to transition all models to CARE, which is expected to cover 90% of clinically relevant diseases, including oncology conditions and cardiovascular diseases, within three years.

Aidoc’s previous funding rounds include a $27 million Series B in 2019, $47 million in 2020, $66 million Series C in 2021, and $110 million Series D in 2022.

The expansion into oncology reflects a broader shift in healthcare toward precision diagnostics and faster clinical decision-making. As cancer remains one of the leading global health challenges, tools that help physicians detect, track, and treat the disease more efficiently can significantly impact survival rates and overall patient care.

Industry experts suggest that Aidoc’s focus on oncology–driven AI will not only strengthen its position among healthcare technology leaders but also bring greater accessibility of advanced diagnostics to hospitals that lack the resources to develop such tools independently. This move signals a future where more health systems can benefit from scalable platforms designed to improve outcomes across oncology, cardiovascular, and other complex conditions.